Rifampin Shortage: What Providers and Prescribers Need to Know in 2026

The rifampin injection shortage has been ongoing since 2021 and continues to affect hospital formularies and TB treatment programs in 2026. With Sanofi's Rifadin IV permanently discontinued and Viatris's product in a current shipping-delay shortage, prescribers need to be prepared with alternative strategies, clear patient communication, and efficient access tools. This guide covers the clinical essentials.

Current Shortage Status (June 2026)

The FDA Drug Shortage Database lists two rifampin injection products as unavailable as of June 2026:

Rifadin IV (Sanofi-Aventis), 600 mg/10 mL: Permanently discontinued. Reverified June 22, 2026. No anticipated return to market.

Rifampin Injection (Mylan Institutional / Viatris), 600 mg/10 mL: Current shortage due to shipping delay. Next release expected July 2026. Wholesalers may have limited available inventory — check distributors (McKesson, Cardinal Health, AmerisourceBergen).

Rifampin oral capsules (150 mg, 300 mg): Not in a formal FDA shortage. Multiple generic manufacturers. Generally available at outpatient pharmacies.

Clinical Implications: Which Patient Populations Are Most at Risk?

The injectable shortage disproportionately affects:

Hospitalized patients with active TB who are NPO (nil per os) or cannot take oral medications

Patients with TB meningitis, where IV rifampin is often clinically preferred due to CNS penetration concerns

Post-surgical or ICU patients with rifampin in their regimens (e.g., prosthetic joint infections)

Pediatric patients in whom oral suspension is prepared from injectable vials

Shortage Management Strategies for Prescribers

1. Transition Stable Patients to Oral Therapy

For hospitalized TB patients who are hemodynamically stable and able to swallow, oral rifampin 600 mg capsules (two 300 mg capsules) is bioequivalent to IV rifampin in most cases. The oral route is preferred as soon as patients can tolerate it. Bioavailability of oral rifampin capsules taken on an empty stomach is approximately 68–90% and is clinically adequate for most indications.

2. Consider Rifabutin as a Rifampin Substitute

Rifabutin (Mycobutin) has comparable efficacy to rifampin in treating drug-susceptible TB. It is the preferred rifamycin when:

The patient is HIV-positive and taking a boosted protease inhibitor or certain integrase inhibitors

The patient has rifampin-related adverse effects (e.g., drug reaction, hepatotoxicity at standard doses)

Note: Rifabutin is a less potent CYP3A4 inducer than rifampin, so dose adjustments for co-administered medications may differ. Consult current TB guidelines or an infectious disease pharmacist for specific rifabutin dosing when substituting for rifampin.

3. Explore Rifapentine-Based Regimens for LTBI

For LTBI patients, the 3HP regimen (3 months of once-weekly isoniazid + rifapentine) is a CDC-preferred option with superior completion rates compared to 9-month isoniazid monotherapy. Rifapentine (Priftin) is generally available and is not currently in shortage. Prescribers managing LTBI patients should consider 3HP or the 1HP regimen (1 month of daily isoniazid + rifapentine) as first-line alternatives to 4-month rifampin monotherapy (4R) during periods of supply constraint.

4. Leverage Public Health TB Programs

State and local health departments have dedicated TB drug supplies, often funded through CDC TB Elimination grants. Prescribers should establish or strengthen their referral pathways to local TB clinics for:

Directly Observed Therapy (DOT) for active TB patients

Drug supply for uninsured or underinsured TB patients

Access to specialty drugs during shortage conditions

Nitrosamine Impurity Update

Since August 2020, the FDA has been investigating nitrosamine impurities (1-methyl-4-nitrosopiperazine, MNP) in rifampin samples. As of 2026, no product recalls have been issued, and the clinical benefit of rifampin continues to outweigh the theoretical nitrosamine risk for patients with active or latent TB. Prescribers should continue using rifampin per standard guidelines while monitoring for any FDA safety communications.

How medfinder Can Help Your Patients

For patients prescribed oral rifampin capsules who struggle to find stock locally, medfinder is a service that contacts pharmacies near your patient's location to find which ones can fill their prescription. Results are texted directly to the patient. This is particularly useful during localized stock-outs and can prevent dangerous treatment interruptions.

Key Takeaways for Providers

Rifampin injection is in active shortage — transition patients to oral therapy as soon as clinically appropriate

Rifabutin is the preferred substitute when rifampin must be avoided (HIV/TB co-infection, intolerance)

For LTBI, 3HP or 1HP regimens with rifapentine are strong alternatives to 4R

Public health TB clinics remain an essential resource for medication supply, DOT, and patient support

Oral capsule availability is generally stable — use medfinder to help patients find local stock when needed

Related Resources

How to help your patients find Rifampin in stock: A provider's guide

Rifampin shortage update: What patients need to know in 2026